Status:
ENROLLING_BY_INVITATION
Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan
Lead Sponsor:
Queen Mary University of London
Collaborating Sponsors:
Aga Khan University
Dow University of Health Sciences
Conditions:
Hepatitis C
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
This trial is linked to a largescale observational study determining the efficacy of sofosbuvir/daclatasvir in people in Pakistan (involving a separate protocol). The observational study will identify...
Detailed Description
Chronic infection with the hepatitis C virus (HCV) causes liver damage and, in many, liver cancer. We have effective drugs allowing us to cure most infected people and this stops the liver becoming da...
Eligibility Criteria
Inclusion
- Willing and able to give written informed consent or sign consent forms with a fingerprint.
- Male or female, age ≥ 18 years.
- Willing to comply with study procedures
- Resident in the area and not planning to leave the region.
- Have a confirmed diagnosis at the time of screening of active hepatitis C infection - defined as detectable HCV RNA using a molecular diagnostic assay with a sensitivity of \>100IU/ml OR detectable HCV Core antigen using an assay with a sensitivity of \>1.5 pg/ml.
- Treatment experience within the last 24 months of antiviral therapy drugs recommended by the government program and administered in line with national recommendations. The current recommendations are that patients without cirrhosis should receive sofosbuvir 400 mg per day in combination with daclatasvir 60 mg per day for a total of 12 weeks and for patients with cirrhosis therapy should involve sofosbuvir 400 mg per day in combination with daclatasvir 60 mg per day for a total of 24 weeks. Patients who receive additional medication (including ribavirin) can be enrolled in the study but the additional medication should be noted.
- The subject's medical records must include sufficient detail of prior treatment to confirm eligibility.
- Have a stored sample of serum or plasma that is known to contain detectable HCV RNA and which can be made available to the study team or be willing to provide such a sample
- Have undergone, or be willing to undergo, an approved screening test for determining liver cirrhosis either by:
- APRI score - calculated from serum AST concentration in IU/L and platelet count /L (a result of ≥2 demonstrates presence of cirrhosis)
- Liver transient elastography assessment (a 'Fibroscan'). A result of ≥12.5 kPa will demonstrate cirrhosis.
- liver biopsy within 1 year of screening
- Females of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 prior to enrolment.
- Lactating females must agree to discontinue nursing before starting study drug.
- Subjects must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
Exclusion
- Unwilling or unable to give consent
- Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol.
- History of discontinuation the most recent regime due to an adverse event
- Co-morbidities limiting life expectancy to less than 12 months
- Gastrointestinal disorder that could interfere with the absorption of the study drugs
- Significant cardiac disease
- Unstable psychiatric condition
- Significant drug allergy (e.g. hepatotoxicity)
- Infection with hepatitis B virus (HBV) or Human immunodeficiency virus (HIV)
- Unable or unwilling to undergo the necessary procedures - undergoing blood testing and ultrasound/fibroscan scanning.
- Previous poor compliance with medication (defined as failure to take \>80% of the prescribed medication)
- Have undergone liver or other solid organ transplantation
- Have a current or recent diagnosis of hepatocellular carcinoma or any other malignancy
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
318 Patients enrolled
Trial Details
Trial ID
NCT05248919
Start Date
June 1 2023
End Date
September 1 2027
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical trials unit
Karachi, Sindh, Pakistan